ExploRNA Therapeutics is a spin-off from the University of Warsaw, developing next generation mRNA technology for applications such as anti-cancer vaccines.
ExploRNA Therapeutics was founded by Professor Jacek Jemielity, Head of the Bio Organic Chemistry Laboratory at the Center of New Technologies CeNT at the University of Warsaw. Professor Jemielity’s first generation ‘cap modification’ mRNA technology was licensed in 2011 to the German company BioNTech.
According to the company, it’s next generation mRNA (with modified 5′ cap encoding neoantigens) is expected to have significantly improved benefits in stability, translational efficiency, and cost of synthesis.
ExploRNA’s two lead development programs will focus on tumor specific antigen vaccines and the expression of cytokines to promote cytotoxic T cells to eliminate tumor growth.
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies …
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness …
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
